Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 39393406

Drug Profile

JNJ 39393406

Alternative Names: JNJ-39393406

Latest Information Update: 07 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen Pharmaceutica; National Institutes of Health (USA); University of Pittsburgh
  • Class Antidementias; Nootropics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders; Smoking withdrawal
  • Discontinued Alzheimer's disease; Schizophrenia

Most Recent Events

  • 15 Feb 2016 Johnson & Johnson Pharmaceutical Research plans the exploratory phase II JNJ-DEP trial for Depressive disorders in Romania (PO, Capsule) (NCT02677207)
  • 01 Feb 2016 Phase-II clinical trials in Depressive disorders in Romania (PO) (NCT02677207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top